| Literature DB >> 32380770 |
Markus Braun1, Doris Klingelhöfer1, Gerhard M Oremek1, David Quarcoo1, David A Groneberg1.
Abstract
Children are commonly exposed to second-hand smoke (SHS) in the domestic environment or inside vehicles of smokers. Unfortunately, prenatal tobacco smoke (PTS) exposure is still common, too. SHS is hazardous to the health of smokers and non-smokers, but especially to that of children. SHS and PTS increase the risk for children to develop cancers and can trigger or worsen asthma and allergies, modulate the immune status, and is harmful to lung, heart and blood vessels. Smoking during pregnancy can cause pregnancy complications and poor birth outcomes as well as changes in the development of the foetus. Lately, some of the molecular and genetic mechanisms that cause adverse health effects in children have been identified. In this review, some of the current insights are discussed. In this regard, it has been found in children that SHS and PTS exposure is associated with changes in levels of enzymes, hormones, and expression of genes, micro RNAs, and proteins. PTS and SHS exposure are major elicitors of mechanisms of oxidative stress. Genetic predisposition can compound the health effects of PTS and SHS exposure. Epigenetic effects might influence in utero gene expression and disease susceptibility. Hence, the limitation of domestic and public exposure to SHS as well as PTS exposure has to be in the focus of policymakers and the public in order to save the health of children at an early age. Global substantial smoke-free policies, health communication campaigns, and behavioural interventions are useful and should be mandatory.Entities:
Keywords: allergy; asthma; atopy; environmental tobacco smoke; genetic predisposition; immunity; maternal tobacco smoke; passive smoke; smoking in pregnancy; wheezing
Year: 2020 PMID: 32380770 PMCID: PMC7246681 DOI: 10.3390/ijerph17093212
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Adverse health effects in children induced by second-hand smoke and prenatal tobacco smoke exposure. COPD = chronic obstructive pulmonary disease.
Summary of changes in children induced by second-hand smoke (SHS) and prenatal tobacco smoke (PTS) exposure.
| Topic | Effects on Children | Test Material | Source | Association |
|---|---|---|---|---|
|
| ||||
| Matrix metalloproteinase-9 (MMP-9) | MMP-9 increased | Nasal secretion | SHS | Allergy, asthma, chronic bronchitis [ |
| Cytokine Interleukin (IL) | IL-1β increased | Saliva | SHS | Inflammatory processes [ |
| IL-1β decreased | Blood | SHS | Inflammatory processes [ | |
| IL-4 decreased | Blood | SHS | Inflammatory processes [ | |
| IL-5 decreased | Blood | SHS | Inflammatory processes [ | |
| IL-6 increased | Saliva | SHS | Inflammatory processes [ | |
| IL-8 increased | New-born dried blood | PTS | Inflammatory processes [ | |
| IL-8 | Nasal secretion | SHS | no effect by SHS [ | |
| IL-8 | Saliva | SHS | no effect by SHS [ | |
| IL-13 increased | Airway secretion | SHS | Inflammatory processes [ | |
| IL-17 | Nasal secretion | SHS | no effect by SHS [ | |
| Cytokine Interferon gamma (IFN-γ) | IFN-γ decreased | Blood | SHS | Inflammatory processes [ |
| Tumour necrosis factor alpha (TNF-α) | TNF-α increased | Saliva | SHS | Inflammatory processes [ |
| Urinary leukotriene E4 (uLTE4) | uLTE4 increased | Urine | SHS | Asthma [ |
| Estimated glomerular filtration rate (eGFR) | eGFR decreased | Serum | SHS | Kidney function, proteinuria [ |
| Intercellular adhesion molecule 1 (s-ICAM1) | s-ICAM1 increased | Serum | SHS | Endothelial stress [ |
| Intima-media thickness (IMT) | IMT increased | Ultrasonography | SHS, PTS | Atherosclerosis [ |
| C-reactive protein (CRP) | CRP increased | Serum | SHS | Inflammation response [ |
|
| ||||
| Regulatory T-cells (Tregs) | Treg cell number decreased | Cord blood, blood | PTS, SHS | Atopy, asthma [ |
| T-helper 17 (Th17) cells | Th17 cell number increased | Blood | SHS | Asthma severity [ |
| T-cells subsets | Circulating CD3+ and CD4+ memory T-cell number decreased | Blood | SHS | Systemic immunological response [ |
| Circulating CD3+ and CD4+ naïve T-cell number increased | Blood | SHS | Systemic immunological response [ | |
| CD4+CD45RA+ T-cell number increased | Blood | SHS | Systemic immunological response [ | |
| CD8+ T-cell number decreased | Adenoids | SHS | Systemic immunological response [ | |
| Immunoglobulins A and M (IgA, IgM) | IgA and IgM increased | Adenoids | SHS | Systemic immunological response [ |
| Immunoglobulin E (IgE) | Immune response to allergens increased | Serum | SHS | Allergy [ |
|
| ||||
| High-density lipoprotein-cholesterol (HDL-C) | HDL-C decreased | Blood | SHS, PTS | Arteriosclerosis, obesity, metabolic syndrome [ |
| Low-density lipoprotein-cholesterol (LDL-C) | LDL-C increased | Blood | SHS, PTS | Arteriosclerosis, obesity, metabolic syndrome [ |
| Triglycerides | Triglycerides increased | Blood | SHS, PTS | Arteriosclerosis, obesity, metabolic syndrome [ |
| Apolipoprotein A-1 (ApoA-1) | ApoA-1 decreased | Blood | SHS | Arteriosclerosis, obesity, metabolic syndrome [ |
| Apolipoprotein B (ApoB) | ApoB increased | Blood | SHS | Arteriosclerosis, obesity, metabolic syndrome [ |
|
| In general: cell, tissue and organ injury, cell death; asthma, COPD, cardiovascular events, metabolic syndrome [ | |||
| Nicotinamide adenine dinucleotide phosphate oxidase-2 (Nox2) | Nox2 increased | Serum | SHS | Artery dilation [ |
| Adiponectin | Adiponectin decreased | Cord blood | PTS | Lipid peroxidation increased [ |
| Pre-B-cell colony enhancing factor (Visfatin) | Visfatin increased | Cord blood | PTS | Lipid peroxidation increased [ |
| Urinary 15-F2t-isoprostane | Urinary 15-F2t-isoprostane increased | Urine | SHS | Lower lung function parameters [ |
| Histone deacetylase-2 (HDAC2) | HDAC2 decreased | Broncho-alveolar lavage fluid | SHS | Corticosteroid-insensitiveness leads to impairment of severe asthma treatment [ |
|
| In general: Metabolic and endocrine dysfunction (foetal, in childhood, and later life) [ | |||
| Ghrelin | Ghrelin increased until early adulthood by PTS exposure | Plasma | PTS | Metabolic disorders [ |
| Leptin | Leptin increased | Plasma | SHS | Impairing of vascular function, BMI [ |
| Adiponectin | Adiponectin decreased | Cord blood | PTS | OS increased, lipid peroxidation increased [ |
| Luteinizing hormone (LH) | In girls, LH decreased by PTS exposure but increased by current SHS exposure | Blood | PTS, SHS | Reproductive development [ |
| Inhibin B (InB) | In girls, InB decreased by PTS exposure with no effect by current SHS exposure | Blood | PTS, SHS | Reproductive development [ |
| Thyrotropin (TSH) | TSH decreased | Serum | SHS | Hypothyroidism, BMI [ |
| Foetal triiodothyronine (T3), thyroxine (T4) and TSH | T3, T4 and TSH decreased (possibly by downregulation of foetal thyroid transcripts GATA6 and NKX2-1) | Foetal plasma | PTS | Disorder of foetal thyroid development and endocrine function [ |
| Foetal corticotropin-releasing hormone (CRH), adrenocorticotrophin (ACTH), cortisol, gonadotropins, androgens, oestrogens | Changes in foetal steroidogenesis | Foetal plasma | PTS | Multiple pathophysiological effects (foetal and later in life) by endocrine dysfunction [ |
Summary of addressed single nucleotide polymorphisms (SNPs) regarding genetic predisposition to tobacco smoke susceptibility.
| Gene (Chromosome) | SNP | Risk Allele | Association |
|---|---|---|---|
| GSTP1 Exon 5 (11q13) | rs1695 (Val-105 or Ile105Val) | AG (Ile105Val) | Early childhood wheezing [ |
| GG (Val105Val) | Asthma [ | ||
| AA (Ile105Ile) | + low vitamin A intake: asthma [ | ||
| GSTP1 Intron 5 (11q13) | rs749174 | TT | Early childhood wheezing [ |
| GSTP1 Intron 6 (11q13) | rs1871042 | TT | Early childhood wheezing [ |
| TNF Promoter (6p21) | rs1800629 (-308) | AA/AG | Respiratory illness [ |
| TNF Promoter (6p21) | rs1799724 (T-857C) | CC | Early childhood wheezing [ |
| TNF Intron 1 (6p21) | rs1800610 | CC | Early childhood wheezing [ |
| TNF Intron 3 (6p21) | rs3093664 | AG/GG | Early childhood wheezing [ |
| TGFB1 Promoter (19q13) | rs4803457 (C-509T) | TT | Asthma [ |
| IL-4 (5q31) | rs2243250 (C-589T) | TT/CT | Wheezing [ |
| IL-13 Exon 4 (5q31) | rs20541 (G/A) | GG | Early onset persistent wheeze and persistent asthma [ |
| IL-13 haplotype pair (Promoter, Intron 1, Exon 4) (5q31) | rs1800925 (C/T), rs2066960 (C/A), rs20541 (G/A) | CCG/CCG | Early onset persistent wheeze and persistent asthma [ |
| CD14 (5q31) | 3’untranslated region (UTR) | AA | Lower IgE levels [ |
| CD14 Promoter (5q31) | rs2569190 (C-159T) | TT | Elevated IgE levels, atopy [ |
| CD14 (5q31) | C-550T | TT | Elevated IgE levels, atopy [ |
| IKZF3 Intron 3 (17q21) | rs9303277 | C | Increased risk of early-onset asthma enhanced by SHS [ |
| ZPBP2 Exon 2 (17q21) | rs11557467 (I151S) | G | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Exon 8 (17q21) | rs2305480 (P298S) | G | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Exon 8 (17q21) | rs2305479 (G291R) | C | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Intron (17q21) | rs4795400 | C | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Intron (17q21) | rs9303281 | A | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Intron 1 (17q21) | rs7219923 | T | Increased risk of early-onset asthma enhanced by SHS [ |
| GSDMB Intron 2 (17q21) | rs2290400 | C | Increased risk of asthma in Caucasians enhanced by SHS [ |
| GSDMB Intron 2 (17q21) | rs7216389 | T | Increased risk of asthma in Caucasians enhanced by SHS [ |
| GSDMA Exon 2 (17q21) | rs3894194 | A | Increased risk of asthma in Caucasians enhanced by SHS [ |
| GSDMA Intron 6 (17q21) | rs3859192 | ? | Increased risk of asthma in Caucasians enhanced by SHS [ |
| ORMDL3 Intron (17q21) | rs8076131 | A | Increased risk of early-onset asthma enhanced by SHS [ |
| LRRC3C Intron (17q21) | rs8079416 | ? | Increased risk of asthma in Caucasians enhanced by SHS [ |
| Intergenic region (17q21) | rs8069176 | G | Increased risk of early-onset asthma enhanced by SHS [ |
| Intergenic region (17q21) | rs4795405 | C | Increased risk of early-onset asthma enhanced by SHS [ |
| Intergenic region (17q21) | rs4794820 | G | Increased risk of early-onset asthma enhanced by SHS [ |
| Intergenic region (17q21) | rs8067378 | ? | Increased risk of asthma in Caucasians enhanced by SHS [ |
| DNAH9 Intron (17p11) | rs7225157 | ? | Bronchial hyperresponsiveness [ |
| ATP8A1 Intron (4p13) | rs17448506 | ? | Bronchial hyperresponsiveness [ |
| ABCA1 Intron (9q31) | rs2253304 | ? | Bronchial hyperresponsiveness [ |
| MBL2 (10q21) | rs5030737 | AA | Increased risk of lung cancer in later life [ |
| MBL2 Intron (10q21) | rs1838066 | CC | Increased risk of lung cancer in later life [ |
| MBL2 Intron (10q21) | rs7095891 | TT | Increased risk of lung cancer in later life [ |
| MBL2 (10q21) | rs2165810 | TT | Increased risk of lung cancer in later life [ |
| FMO3 (1q24) | rs2266782 (G472A) | AA | Risk factor for sudden infant death syndrome [ |
| OSGEP Intron (14q11) | rs1320150 | AG | Increased risk of congenital heart defects [ |
| OSGEP Intron (14q11) | rs938881 | ? | Increased risk of congenital heart defects [ |
| OSGEP (14q11) | rs2275007 | ? | Increased risk of congenital heart defects [ |
| OSGEP Intron (14q11) | rs883037 | ? | Increased risk of congenital heart defects [ |
| MSX1 Intron allele 4 (4p16) | Homozygosity of 9 repeats of the A4 CA marker | Increased risk of nonsyndromic orofacial clefts [ |
Additional information was given from the National Center for Biotechnology Information (NCBI) of the U.S. National Library of Medicine database [156]. The table presents risk alleles associated with a disease. ? = risk allele not reported. SNP = single nucleotide polymorphism. A = adenine. C = cytosine. G = guanine. T = thymine.